Showing 43,021 - 43,040 results of 61,162 for search '(( 5 ((teer decrease) OR (we decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 1.48s Refine Results
  1. 43021

    Table_7_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  2. 43022

    Table_10_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  3. 43023

    Table_6_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  4. 43024

    Table_3_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  5. 43025

    Table_4_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  6. 43026

    Table_2_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  7. 43027

    Table_1_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  8. 43028

    Table_8_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  9. 43029

    Equilibrium conditions for all combinations of <i>μ</i> and <i>e</i> tested here. by L. S. Premo (234955)

    Published 2010
    “…<p>Richness decreases quickly from an initial value of 2500 and cultural diversity reaches equilibrium by the 50,000<sup>th</sup> time step in all populations. …”
  10. 43030

    Improving the measurement of TMS-assessed voluntary activation in the knee extensors by Jeanne Dekerle (800587)

    Published 2019
    “…In a fresh state, potentiated twitch force was unchanged following 1x5C but decreased following 2x5C (<i>P</i><0.05). …”
  11. 43031

    Dietary net energy for gilts from 25 to 100 kg body weight by Danilo Alves Marçal (5837930)

    Published 2018
    “…Corn-soybean meal-based diets were formulated to be fed in three phases (25 to 50, 50 to 70, and 70 to 100 kg BW). Soybean oil was added to replace the inert ingredient kaolin to meet the NE level of each diet. …”
  12. 43032

    FGFR2 is required for growth of NCI-H716 cells. by Anjili Mathur (163690)

    Published 2014
    “…Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. …”
  13. 43033
  14. 43034
  15. 43035
  16. 43036
  17. 43037

    QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells by Neha Laxane (19851759)

    Published 2024
    “…</p> <p><b>Conclusion:</b> Formulated nanoparticles had a low IC<sub>50</sub> value and enhanced cellular uptake.…”
  18. 43038
  19. 43039
  20. 43040

    Stability of an anaerobic single reactor filled with dolomitic limestone with increased organic load of sugarcane by Maria Magdalena Ribas Döll (4680364)

    Published 2017
    “…This bench reactor was filled with dolomitic limestone with a horizontal plug flow to simulate a drainage channel. …”